Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study by Sánchez Durán, Maria Ángeles et al.
RESEARCH ARTICLE Open Access
Clinical application of a contingent
screening strategy for trisomies with
cell-free DNA: a pilot study
María Ángeles Sánchez-Durán1,2, Andrea Bernabeu García1,2, Inés Calero1,2, Jordi Ramis Fossas2,3, Tamara Illescas1,2,
María Teresa Avilés1,2, Nerea Maiz1,2* and Elena Carreras1,2
Abstract
Background: Different strategies have been designed for clinical implementation of cell-free DNA (cfDNA) testing.
We aimed to evaluate the performance of a contingent strategy based on conventional screening and offering
cfDNA to the intermediate-risk group, for the screening for trisomies 21, 18 and 13. Secondary objectives were to
assess the uptake of cfDNA in women with intermediate-risk, to evaluate the performance of cfDNA testing, and
the preferences of pregnant women with intermediate risk.
Methods: Prospective observational pilot study between February 2016 and March 2017. Singleton pregnancies
with a known outcome were included in the study. At the conventional screening (first trimester combined test or
second trimester quadruple test) women were classified in high (risk ≥1:250) or low risk (< 1:250). For the study, a
contingent strategy was applied: following the conventional screening women were classified into three groups:
high risk (risk ≥1:10 or nuchal translucency ≥3 mm), intermediate-risk (risk 1:11 to 1:1500) and low risk (< 1:1500),
and a cfDNA test was offered to those at the intermediate risk.
Results: For the analysis, 2639 women were included, 2422 (91.8%) had a first trimester combined test and 217
(8.2%) a second trimester quadruple test. There were 5 cases of trisomy 21, 4 of trisomy 18 and none of trisomy 13.
For the contingent strategy, the detection rate and false positive rates were 88.9% (8/9) and 1.3% (35/2630),
respectively. For the conventional strategy, the detection rate and false positive rates were 66.7% (6/9) and 5.3%
(140/2630), respectively. The cfDNA test had a detection rate for trisomy 21 of 100% (3 out of 3), and a false
positive rate of 0.2% (1/466). In a survey, 81.8% (374/457) of women in the intermediate-risk group would choose
cfDNA testing as the second line test, mainly due to the lack of risk for the fetus.
Conclusion: A contingent screening strategy for trisomies 21, 18 and 13, based on conventional screening, and
offering a cfDNA test to women with a risk between 1:11 to 1:1500, reduced the false positive rate and increased
the detection rate for these trisomies. Moreover, this strategy is well accepted by women.
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Background
First trimester combined testing has become the stand-
ard screening strategy for Down syndrome, with a detec-
tion rate of 90% for trisomy 21, 95% for trisomies 18 and
13, and a false positive rate of 5% [1]. More recently, the
study of cell-free DNA (cfDNA) in maternal blood has
shown higher detection rates [2, 3], with an important
reduction in false positive rates, minimizing the number
of invasive procedures and their complications. The
universal use of cfDNA testing is controversial due to
concerns about cost. An alternative is a contingent
strategy in two steps; firstly a conventional screening is
performed, and secondly, a cfDNA test is offered only to
those patients with intermediate-risk. This strategy
would increase the detection rate and reduce the false
positive rate [4].
The aim of the study was to assess the performance of
the contingent screening for trisomies 21, 18 and 13.
Secondary objectives were to assess the uptake of cfDNA
in women with intermediate-risk, to evaluate the
performance of cfDNA testing, and the preferences of
pregnant women with intermediate risk.
Methods
Study design and population
This was a prospective observational study performed
between February 2016 and March 2017 at Vall d’Heb-
ron University Hospital, Barcelona, Spain. This was a
pilot study, previous to the implementation of a contin-
gent strategy based on conventional screening (first tri-
mester combined test and second-trimester quadruple
test) and offering cfDNA to the intermediate-risk group
at the public health system in our region,
The study population was women referred consecu-
tively to the hospital for aneuploidies screening. Eligible
patients were at least 18 years of age, with a singleton
pregnancy. Exclusion criteria were vanishing twin preg-
nancy and unknown karyotype or unknown neonatal
phenotype. This study was approved by the institutional
research ethics committee (CEIC-VHIR) and informed
consent was obtained from all women included in this
study.
Clinical protocol
As required in the regional prenatal screening protocol,
all pregnant women were offered to screen for fetal tri-
somies at the first prenatal care visit. The first-trimester
screening protocol included measurement of serum con-
centration of β-human chorionic gonadotropin (β-hCG)
and pregnancy-associated plasma protein-A (PAPP-A) at
8 to 12 weeks, and an ultrasound scan at 11+ 0 to 13+ 6
weeks, where fetal crown-rump length [CRL] and nuchal
translucency were measured. Subsequently, the risk for
trisomies 21, 18 and 13 was calculated combining all
these data, according to prenatal diagnosis protocol for
fetal congenital anomalies [5]. A second trimester quad-
ruple test, including measurement of serum β-hCG,
alpha-fetoprotein, unconjugated-oestriol, and inhibin-A,
was offered to those women attending the screening
antenatal clinic after 13 + 6 weeks.
Conventional screening
In the routine clinical practice, following first trimester
combined test or second trimester quadruple test
women were classified into two groups: high-risk, if the
risk for trisomies 21, 18 or 13 was ≥1:250 or the nuchal
translucency ≥3 mm, and low risk, if the risk was
lower than 1:250. An invasive test was offered to
women at high risk. In the low-risk group, no add-
itional tests were offered and a second trimester scan
was scheduled (Fig. 1).
Contingent screening (study)
For the study, women were classified in three groups
following the conventional screening: High-risk (risk ≥1:
10 or nuchal translucency ≥3 mm), intermediate-risk
(risk between 1:11 and 1:1500) and low-risk (risk < 1:
1500). An invasive test was offered to women at high
risk, no further test to women at low risk, and a cfDNA
test was offered to those with intermediate-risk. Never-
theless, if the risk was between 1:11 and 1:250 addition-
ally an invasive test was offered, according to the
national screening protocol (Fig. 2).
A chorionic villus sampling or amniocentesis was
carried out depending on gestational age. Prenatal diag-
nostic results of chromosomes 13, 18, 21, X and Y were
released within 48 h of sample collection using QF-PCR
and results of all chromosomal abnormalities were re-
leased with a time frame of 2–3 weeks by karyotype and/
or array analysis.
Regarding cfDNA, peripheral maternal blood (20 mL)
was collected into a standard ethylenediaminetetraacetic
acid blood collection tube during the screening visit and
sent via courier to the USA for cfDNA testing (Har-
mony® prenatal test, Ariosa Diagnostics, Inc., San Jose,
CA, USA).
Genetic counseling was carried out by a trained obstet-
rician and screening results of the most common triso-
mies (21, 18 and 13) were expected to be obtained
within 7–10 days. Women with a screen-positive result
(high-risk result from cfDNA testing) were advised to
have an invasive procedure in order to confirm the
diagnosis, whereas women with a screen-negative result
(low-risk result from cfDNA testing) continued conven-
tional obstetric control during pregnancy as low-risk
patients.
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After cfDNA results delivery, women were asked to fill
out an anonymous survey concerning the available
contingent second-line options (Additional file 1).
All pregnant women were followed up until the end of
pregnancy and all the newborns were studied for a
phenotype by a pediatrician and a karyotype was re-
quested if necessary.
Study variables
Demographic maternal characteristics, including mater-
nal age, weight, and race, were collected in the study
electronic database by obstetricians during the screening
visit. The risks for trisomies 21, 18 and 13 and the pro-
cedure performed after screening (invasive test, cfDNA
or routine obstetric control) were collected in the data-
base. We recorded the invasive test results, the cfDNA
results (risk for trisomy 21, 18 or 13, fetal fraction in
cfDNA from maternal plasma, test with no results, repe-
titions and time for result) and perinatal results of
pregnancy.
The primary outcome of this study was the perform-
ance (detection rate and false positive rate) of the
contingent strategy based on conventional screening and
using cfDNA in the screening for trisomy 21, 18 and 13.
Fig. 1 Conventional screening strategy
Fig. 2 Contingent screening strategy
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Secondary outcomes were the detection rate and false
positive rates of the cfDNA test, as well as the prefer-
ences of pregnant women.
Statistical analysis
For the descriptive analysis, categorical data are shown
as frequency and percentage, and continuous variables
as the median and interquartile range (IQR). Pearson
correlation was used to determine the association
between fetal fraction and body mass index (BMI), and
between the fetal fraction and the gestational age. Detec-
tion rate and false positive rate of both conventional and
contingent screening strategies were calculated. Statis-
tical significance level was set at p < 0.05. The statistical
software package SPSS 23.0 (IBM SPSS Statistics for
Windows, Version 23.0. Armonk, NY: IBM Corp) was
used for the analysis of the data.
Results
Study population
Two thousand nine hundred and eighty-six patients
were screened in this period, 2706 women were eligible
for the study, from these 67 (2.5%) were excluded, 2639
women were included for analysis, 2422 (91.8%) who
had a first trimester combined test and 217 (8.2%) a sec-
ond trimester quadruple test (Fig. 3). In this population,
there were 5 cases of trisomy 21, 4 of trisomy 18 and no
cases of trisomy 13 (Table 1).
Median maternal age was 32.1 years (IQR, 28.1 to
36.0) and median weight 63 kg (IQR, 55.2 to 72.0). Two
thousand three hundred and seven women (87.4%) were
Caucasian, 131 (5.0%) North African, 73 (2.8%) Sub-Sa-
haran, 71 (2.7%) East Asian, 51 (1.9%) South Asian and
6 (0.2%) mixed race.
Conventional screening
According to the conventional test (first trimester com-
bined test or second trimester quadruple test), 146 of
2639 (5.5%) women had a high risk (screen positive rate)
and 2493 (94.5%) had a low risk (Fig. 1). The detection
rate for all trisomies (trisomy 21, 18 and 13) was 66.7%
(6/9) and the false positive rate 5.3% (140/2630). The
specific detection rates for trisomy 21 and 18 were 60%
(3/5), and 75% (3/4), respectively.
Contingent screening
Following the conventional screening 33 (1.3%) women
had a high risk (14 with a risk of 1:10 or more, and 19
fetuses with nuchal translucency of 3 mm or more), 496
(18.8%) patients had an intermediate risk (between 1:11
and 1:1500) and 2110 (79.9%) women had a low risk
(< 1:1500).
From the 496 women with intermediate-risk 27 (5.4%)
declined cfDNA testing, 7 had an invasive test (5 of
them had a high risk), 2 had a cfDNA in a private center,
one miscarried, one moved to another city, one refused
due to difficulties for blood extraction and the other 15
refused to give a reason. In the 469 women who had a
cfDNA test, 3 had a high risk for trisomy 21, one had a
high risk for trisomy 13 and 463 had a low risk, and in
two cases no result was obtained after repeating the test
two and three times, respectively. The reason for the no
Fig. 3 Enrollment
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result in both cases was a low fetal fraction. The risk for
Down syndrome at the conventional screening in these
two cases was 1:213 and 1:908, respectively. Both women
who had no result and those who refused cfDNA testing
were reclassified according to the result at the conven-
tional screening. Following the cfDNA testing in the
intermediate-risk group, 43 (1.6%) women had a high
risk (screen positive rate), and 2596 (98.4%) had a low
risk (Fig. 2).
In addition to the cfDNA test, an invasive test was
offered to the group of 113 women with a risk between
1:11 and 1:250, 32 (28.3%) of them declined it and 81
(71.7%) underwent an invasive test.
For the contingent strategy, the detection rate for all
three trisomies was 88.9% (8/9) and the false positive
rate was 1.3% (35/2630). The specific detection rates for
trisomy 21 and 18 were 100% (5/5) and 75% (3/4),
respectively.
Performance of cfDNA test
In the 469 women with intermediate-risk who accepted
cfDNA testing, there were 3 cases of trisomy 21 and
none of trisomy 18 or 13. In one case the result in-
formed of high risk for trisomy 13, and the karyotype
was normal. Median gestational age at cfDNA testing
was 13.2 weeks (interquartile range, 12.5–14.1).
The detection rate for trisomy 21 was 100% (3 out of
3), and the overall false positive rate was 0.2% (1/466).
The test was repeated in 15 (3.2%) women, in 8 cases
due to a sample mismanagement (4 cases where the
samples were not labeled, 4 cases where the sample was
lost during transport), 2 cases had a low fetal fraction
and in 5 cases the samples did not meet quality criteria.
In the second analysis, 12 cases showed a low risk for
trisomies, and three samples again had no results, two of
them were repeated, one had a low risk, and the other
sample had no results for the third time. The latter was
reported as a normal newborn at the end of follow-up.
Regarding the sample which was not repeated, an
invasive test was performed and the result was normal.
The overall no-result rate was 0.43% (2/469). cfDNA
results were issued after a mean of 6.7 (SD2.3) days, 90
and 87% of results were available within 8 and 7 days,
respectively.
The median fetal fraction was 11.9% (IQR, 9.1 to 14.7).
There was a significant correlation between fetal fraction
and BMI, r = -0.364 (95% CI: − 0.356 to − 0.220; p <
0 .001), and there was no significant correlation between
fetal fraction and gestational age (r = 0.086, 95% CI: −
0.013 to 0.354; p = 0.068).
A total of 457 (97.4%) patients at intermediate-risk
filled out the anonymous survey, the remaining patients
of this group did not participate due to a language bar-
rier. The results showed that 374 (81.8%) women would
have preferred cfDNA testing as the second line contin-
gent test, 80 (17.5%) would have preferred an invasive
procedure, and 3 (0.7%) women not doing anything. The
reasons for these answers are given in Table 2. Regarding
the time for results, 239 women (52.3%) considered that
it was short, 184 (40.3%) that it was appropriate, 30
(6.6%) thought that it was too long, and 4 (0.9%) did not
respond to this question.
Discussion
Main findings of the study
This study confirms that a contingent screening strategy,
based on the first trimester combined test or second
trimester quadruple test and offering a cfDNA test to
the intermediate-risk group, can improve the perform-
ance of the screening for trisomies 21, 18 and 13 by both
increasing the detection rate and reducing the false posi-
tive rate. CfDNA was well accepted by this group of
women, with an uptake of 94.6%, including women
classified as ‘high risk’ by the conventional screening
test. The main reason for accepting this test was the lack
of risk for the fetus.
Focusing on the cfDNA test, the performance was ex-
cellent in this small sample, with a detection rate of
Table 1 Description of the 9 cases of aneuploidies
Case Aneuploidy Screening Trimester Risk 1 in Conventional screening cfDNA Contingent screening
1 Trisomy 21 1 3 High risk – High risk
2 Trisomy 21 1 7 High risk – High risk
3 Trisomy 21 1 54 High risk High-risk High risk
4 Trisomy 21 1 596 Low risk High-risk High risk
5 Trisomy 21 2 741 Low risk High-risk High risk
6 Trisomy 18 1 1 High risk – High risk
7 Trisomy 18 1 1 High risk – High risk
8 Trisomy 18 1 1 High risk – High risk
9 Trisomy 18 1 13,735 Low risk – Low risk
cfDNA cell-free DNA
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100% for trisomy 21, and an overall false positive rate of
0.2%. The no-result rate of the test was 0.43% after re-
peating the test up to three times. In a survey after the
screening process, more than 80% of women in the
intermediate-risk group would choose cfDNA testing as
the first option, and more than 90% of women consid-
ered that the time to deliver the results was appropriate.
Compare to the literature
Our findings are similar to those reported by other
groups where a contingent screening, by means of a
cfDNA test in the intermediate-risk group increases the
detection rate and reduces the false positive rate [6, 7].
However, the performance and cost-effectiveness are dif-
ficult to compare among studies where different cut-offs
have been used [8]. The cut-offs chosen in our study
were 1:11 and 1:1500. When we have addressed the issue
of implementing a contingent screening, we have set
two goals: reducing the invasive test rate and increasing
the detection rate. In order to reduce the invasive rate,
we had to offer a cfDNA test to the high-risk group (≥1:
250). We observed that most chromosomal abnormal-
ities were in the group of risk of 1:10 or more, or in
those with a nuchal translucency higher than 3mm. As
a consequence, we opted for this cut-off at the high-risk
site. On the opposite side, we aimed to increase the de-
tection rate and chose 1:1500 based on our own data
and adjusting to our budget.
The no-result rate in our population was 3.2% follow-
ing the first sample collection, and it was reduced to
0.43% after repeating the sample collection up to three
times. Other studies have reported no-results rates for
trisomies up to 5.9% [2].
It is important to highlight that the performance of
the contingent strategy depends on the performance of
the conventional screening (first trimester combined test
or second trimester quadruple test), it is, therefore, im-
portant to maintain the standards of quality for these
screening tests.
Previous studies have shown a reduction in the rate of
invasive testing from 65 to 37% in the high-risk group
(from the combined test) [6]. In our study, only 28% of
women of this group opted to avoid invasive testing. We
believe that this is explained by the lack of confidence of
the women in the test due to the novelty.
Strengths and limitations
The main limitation of this study is the sample size. The
small number of affected fetuses in this cohort does not
guarantee an accurate assessment and, therefore, a study
with a larger sample size would ensure these results.
This study evaluated the feasibility of a contingent
screening in real conditions, where 8% of women missed
the first-trimester screening and had a second-trimester
screening.
The uptake of our study is not comparable to other
studies since this was a pilot study carried out under a
regional clinical protocol, and women could not be
deprived of the options included in this protocol, hence
high-risk patients were offered an invasive procedure
despite participating in the study and having a cfDNA
test.
Clinical implications
The confirmation of the good performance of the con-
tingent strategy, the high uptake and good acceptance of
the test by the patients will permit us to introduce the
contingent screening in the clinical practice modifying
the regional protocol. Invasive testing will remain as
the first choice in cases of increased nuchal translu-
cency, fetal structural abnormalities or risk higher
than 1:10, and as a diagnostic test following a positive
cfDNA result.
Conclusions
A contingent screening strategy for trisomies 21, 18 and
13, based on conventional screening, and offering a
cfDNA test to women with a risk between 1:11 to 1:
1500, reduced the false positive rate and increased the
detection rate for these trisomies. Moreover, this strategy
was well accepted by women.
Table 2 Results of the survey
Q1. Following the conventional screening, which procedure would you have preferred as the first option?
cfDNA (n = 374) Invasive testing (n = 80) No further testing (n = 3)
Q2.Why? Diagnostic accuracy 16 (4.3%) 76 (95.0%) 0
No risk for fetus 349 (93.3%) 1 (1.3%) 0
Earlier diagnosis 2 (0.5%) 1 (1.3%) 0
Othera 7 (1.9%) 2 (2.5%) 3 (100%)
cfDNA cell-free DNA
a Other: cfDNA: 5/7 cases preferred to avoid a painful test; Invasive testing: did not give a specific reason; No further testing: 2/3 cases committed to the
pregnancy. The rest of the cases did not specify a reason
Women’s opinion about available prenatal testing options
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Additional file
Additional file 1: Anonymous survey concerning available prenatal
testing options. (DOCX 12 kb)
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